Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2022-01-01
Serier:Cancer Treatment and Research Communications
Fag:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Online adgang:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker